Comparison of R&D information disclosure of Chinese and foreign listed pharmaceutical enterprises – Take Hengrui Pharmaceutical and Pfizer Pharmaceutical as examples

Abstract

Recently, the demand for epidemic prevention equipment and therapeutic drugs at home and abroad has surged. In order to improve their competitiveness, enterprises have invested a lot of money in drug research and development and medical device innovation.This paper focuses on the research and analysis of the background conditions of drug research and development and information disclosure in China in recent years, and combines and expounds two scientific theoretical foundations related to information disclosure and disclosure, namely information disclosure, asymmetry theory and information transmission theory. Based on the actual situation, a detailed analysis of the Chinese enterprise Hengrui Pharmaceutical and the American enterprise Pfizer Pharmaceutical, the R&D expenditure and the disclosure of R&D expenses of the company in recent years were explained, and the problems and the gap between the two enterprises were found. Finally, suggestions for improvement are made for the above problems.